Treos Bio announces results from trial of precision cancer vaccine

Preliminary outcomes of the first part of the study have been made available and results of the second part are anticipated to be published in the third quarter of this year.

The immuno-oncology company Treos Bio Ltd. has reportedly announced the positive interim outcomes from its first-in-man phase 1/2 trial of its precision cancer vaccine with maintenance therapy in patients enduring metastatic colorectal cancer (mCRC). The results will be presented in a poster session at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3.

Reportedly, PolyPEPI1018 is an off-the-shelf, long peptide vaccine consists of twelve unique epitopes developed from 7 conserved cancer testis antigens (CTAs) regularly stated in mCRC. PolyPEPI1018 was created to bring on polyvalent T cell responses in a large subpopulation of CRC patients leveraging PEPI TestTM platform. This platform identifies Personal EPItopes (PEPIs) which may induce antigen-specific T cell responses in a subject.

Apparently, the Phase 1/2 study is a single-arm, open-label, multicenter study to assess the tolerability, safety, preliminary efficacy and immunogenicity of single (first part of the study) or multiple (second part of the study) subcutaneous injection of PolyPEPI1018 as an additional immunotherapy to the standard-of-care maintenance treatment in patients enduring metastatic colorectal cancer. Preliminary outcomes of the first part of the study have been made available and results of the second part of the study are anticipated to be published in the third quarter of this year.

Immunological data observed so far for PolyPEPI1018 off-the-shelf vaccine against mCRC outperformed has noted immunogenicity of modified neoantigen vaccines and enabled durable treatment effect as supplement to maintenance therapy.

Joleen M. Hubbard M.D., Principal Investigator, OBERTO trial, Mayo Clinic, reportedly stated that despite the single dose of PolyPEPI1018, the company has seen unexpected clinical signals in the first part of the study. Based on these encouraging results, the trial has been amended to administer three doses of PolyPEPI1018 given 12 weeks apart, he further added.

Source link: http://treosbio.com/index.php/may-28-2019/